This FTSE 100 dividend stock will update investors next week! Should you buy it for your ISA?

Looking for big-yielding FTSE 100 shares for your Stocks & Shares ISA? Royston Wild runs the rule over a blue-chip that’s set to release fresh financials.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are several top FTSE 100 shares poised to update the market in the coming days. AstraZeneca, Smith & Nephew and GlaxoSmithKline are just a few of the blue-chips I reckon could surge on the back of upcoming fresh trading numbers, and are therefore shares I consider to be top buys today.

I’m certainly not convinced, however, that stock investors should try to grab a slice of Royal Bank of Scotland before its own financials are released next week. Not even a low forward P/E ratio of 8.7 times or a bulging 11.5% dividend yield are enough to tempt me in right now.

Under pressure

The last couple of trading releases have been less than reassuring, and last time it updated the market in August, it declared that income dropped 1.7% between January to June, reflecting an ultra-competitive landscape (particularly so in the home loans arena) and the steady weakening of the domestic economy.

A wilting top line  wasn’t all that RBS had to swallow, though, the bank also announcing that the number of bad loans had more than doubled in the first half from a year earlier, to £323m from £141m.

Following signs that the UK economy continues to struggle under the weight of Brexit — latest GDP data showed economic output back-peddling 0.1% in August — I’m not expecting anything other than another worrying set of numbers for the third quarter.

Time to sell?

Rising impairments and reversing revenues aren’t the only things I worry about for the days ahead. Six weeks ago, the Footsie bank said that, following a flurry of claims related to the prior mis-selling of payment protection insurance (PPI) ahead of the August 29 deadline, it was setting aside another £600m-£900m to cover the cost of possible penalties.

One piece of good news to come from August’s half-year update was that RBS kept its full-year guidance for 2019 unchanged. Less cheery, however, was that the bank hacked down its expectations for next year.

It advised that “given current market conditions, continued economic and political uncertainty and the contraction of the yield curve,” RBS thinks “it is very unlikely that we will achieve our target return on tangible equity of more than 12% and cost:income ratio of less than 50% in 2020.” Investors should be braced, I believe, for the board’s expectations to be hacked down again for the near-to-medium term and possibly as soon as the days ahead.

The RBS share price is riding the crest of a wave right now. As I type it is dealing at 10-week highs around 230p, boosted by investor hopes that a deal between British and European Union negotiators is edging closer. I consider such optimism to be based on sandy foundations, however, and with those financials just around the corner, I reckon that existing holders of the bank’s stock should use this recent strength as a fresh selling opportunity.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »